Market Exclusive

Allena Pharmaceuticals Inc (NASDAQ:ALNA) had its Outperform rating reiterated by Credit Suisse Group with a $26.00 price target

Analyst Ratings For Allena Pharmaceuticals Inc (NASDAQ:ALNA)

Today, Credit Suisse Group reiterated its Outperform rating on Allena Pharmaceuticals Inc (NASDAQ:ALNA) with a price target of $26.00.

There are 6 Buy Ratings, no Strong Buy Ratings, no Sell Ratings, no Hold Ratings on the stock.

The current consensus rating on Allena Pharmaceuticals Inc (NASDAQ:ALNA) is Buy with a consensus target price of $25.20 per share, a potential 544.50% upside.

Some recent analyst ratings include

About Allena Pharmaceuticals Inc (NASDAQ:ALNA)
Allena Pharmaceuticals, Inc, a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. Read More…

Recent Trading Activity for Allena Pharmaceuticals Inc (NASDAQ:ALNA)
Shares of Allena Pharmaceuticals Inc closed the previous trading session at 3.91 −0.030 0.76% with 26158 shares trading hands.

Exit mobile version